RESEARCH ARTICLE

Trypsin may be associated with duodenal eosinophils through the expression of PAR2 in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities

Shuhei Agawa¹, Seiji Futagami*¹, Hiroshi Yamawaki¹, Rina Tsushima¹, Kazutoshi Higuchi¹, Mayu Habiro¹, Rie Kawawa¹, Yasuhiro Kodaka³, Nobue Ueki¹, Yoshiyuki Watanabe², Katya Gudis¹, Rhuji Ohashi³, Katsuhiko Iwakiri¹

¹ Department of Gastroenterology, Nippon Medical School, Tokyo, Japan, ² Department of Internal Medicine, Kawasaki Rinko General Hospital, Kawasaki, Japan, ³ Department of Diagnostic Pathology, Nippon Medical School, Tokyo, Japan

* seiji.futagami@gmail.com

Abstract

Background

Early chronic pancreatitis (ECP) has been reported to advance into chronic pancreatitis, it may be critical to differentiate the pathophysiology of ECP and functional dyspepsia (FD) in patients with pancreatic enzyme abnormalities (FD-P). This study aimed to clarify differences in the pathophysiology of ECP and FD-P and to determine whether duodenal inflammatory responses in the two diseases were associated with protease-activated receptor (PAR) 2, as the trypsin receptor.

Methods

Eighty patients who presented with FD-P and ECP were enrolled. In duodenal specimens, PAR2 mRNA levels were determined using real-time PCR. Using immunostaining, CD68-, GLP-1-, PRG2-, and CCR2-positive cells, tight junction proteins, and PAR 2 were evaluated.

Results

There were no significant differences in clinical symptoms and gastric motility between ECP and FD-P patients. The CD68-positive cells infiltrations and occludin expression levels in the duodenal mucosa of patients with FD-P were significantly (p<0.001 and p = 0.048, respectively) lower than those in patients with ECP. Although serum trypsin levels in ECP and FD-P patients were significantly (p<0.05 and p<0.001, respectively) associated with duodenal eosinophil counts, elevated trypsin levels were not significantly associated with degranulated eosinophils, occludin, claudin-1 and ZO-1 expression levels in the duodenum of either group. PAR2 mRNA levels were increased in the duodenum of patients with ECP.
Conclusions
Elevated trypsin levels might be partly associated with duodenal inflammatory responses through PAR2-related degranulated eosinophils and the reduction of occludin in patients with ECP and FD-P.

Introduction
The Rome III classification defines functional dyspepsia (FD) patients based on their bothersome abdominal symptoms despite the absence of organic diseases using abdominal ultrasonography or abdominal CT scanning [1,2]. FD can also encompass chronic pancreatitis who are complicated with abdominal fullness, epigastric pain, and early satiety [3]. Andersen et al. and Smith et al. reported that a portion of the population of FD patients had pancreatic enzyme abnormalities and chronic pancreatitis [4,5]. In 2015, the Japanese Society of Gastroenterology (JSGE) reported new guidelines for FD and demonstrated that among FD patients, 24% had chronic pancreatitis (CP) [4,6]. Sahai et al. have also studied that dyspepsia may be an atypical presentation of pancreatic disease as determined by endoscopic ultrasonography (EUS) [3]. In Japan, to prevent the early phase of CP from advancing into CP, new strategies for addressing CP in its initial stages have been proposed [7]. According to the Japan Pancreatic Association (JPA), four clinical criteria including epigastric pain and the presence of more than two features of EUS are needed for a diagnosis of early chronic pancreatitis (ECP) and ECP has been reported to be a high-risk group for advanced CP and pancreatic cancer [7]. We recently conducted a study comparing the clinical characteristics and duodenal inflammation between patients with ECP and FD with pancreatic enzyme abnormalities (FD-P), and both groups had very similar characteristics [8–10].

Thus, since it is critical to treat with ECP and FD-P patients based on the distinct pathophysiology of two groups and to clarify whether pancreatic enzyme abnormalities were associated with duodenal inflammatory responses and refractory symptoms, we tried to analyze whether pancreatic enzyme levels such as trypsin levels affected the expression levels of tight junction proteins or duodenal inflammatory cells infiltrations such as eosinophils through the expression of PAR2 in the duodenum of patients with ECP and FD-P.
Material and methods

Patients

This study enrolled 80 consecutive patients from April 2013 to March 2020, who presented with ECP (n = 26), functional dyspepsia with pancreatic enzyme abnormalities (FD-P) (n = 54) after the measurement of pancreatic enzymes, upper GI endoscopy, abdominal ultrasonography and abdominal computed tomography. Asymptomatic patients without abnormal images (n = 12) were enrolled as controls. According to the none of pancreatic enzyme abnormalities, we first diagnosed FD patients and later the others were divided with the endosonographic findings in ECP and FD-P patients (S1 Fig). Patients with FD were determined by the Rome III criteria [1]. Exclusion criteria included patients with severe heart disease, renal or pulmonary failure, liver cirrhosis, severe systemic illness, and a history of malignant disease. Helicobacter pylori (H. pylori) infection was determined by both the $^{13}$C-urea breath test and by measurement of anti-H. pylori antibody. We measured five kinds of pancreatic enzymes in the sera of FD patients. Written informed consent was obtained from all subjects prior to undergoing upper GI endoscopy and abdominal ultrasonography for the evaluation of dyspeptic symptoms. The study protocol was approved by the Ethics Review Committee of Nippon Medical School Hospital (556-2-21).

Analysis of serum pancreatic enzymes and duodenal trypsin contents

Serum levels of trypsin, PLA2, lipase, p-amylase, and elastase-1, and trypsin levels in the duodenal fluids taken from endosonographies were analyzed using an automated chemistry analyzer (AU 5822 analyzer; Beckman Coulter, Brea, CA, USA).

Clinical symptoms

The clinical symptoms of FD were estimated based on the Rome III criteria [1]. The diagnoses of PDS and EPS were determined with symptoms occurring for the last three months and the onset of symptoms occurring at least six months prior to diagnosis. In this study, each FD symptom was estimated based on the Rome III classification [1] and evaluated as follows: 0, none; 1, very mild; 2, mild; 3, moderate; 4, severe; and 5, very severe. Clinical symptoms were estimated using the Gastrointestinal Symptom Rating Scale (GSRS) [19]. Dyspeptic symptoms were evaluated using the mean GSRS and the 15 GI symptoms of the GSRS.

Clinical symptoms for fat intakes

In this study, high-fat meals were defined as those containing more than 16 grams of fat per 100 grams of food according to previous study [20]. Patients consuming high-fat meals evaluated their own clinical symptom scores as follows: 0, no complaints; and 1, presence of any clinical symptoms including gastroesophageal reflux, abdominal pain, dyspepsia, diarrhea and constipation.

Endosonographic assessment

An Olympus EUS-UCT 260 convex scanning endosonography (Olympus America, Melville, NY, USA) was used to perform EUS under conscious sedation in 80 FD patients with pancreatic enzyme abnormalities (S1 Fig). Endosonographic features were determined as previous study [7]. When there were any differences in opinions among the expert endoscopists, the final diagnosis was determined by consensus following a discussion of each case. Early chronic pancreatitis cases were diagnosed based on the presence of two or more EUS imaging findings, among the seven findings listed above, and the presence of two or more clinical symptoms or
findings, including repeated attacks of epigastric pain, abnormalities in blood/urine pancreatic enzymes, exocrine pancreatic dysfunction and a chronic alcohol intake (80g/day) (S1 Fig).

**RNA extraction and real-time PCR assay for PAR2**

Duodenal tissues were first homogenized and the RNA was extracted from duodenal mucosa samples using an RNA extraction kit (QIAGEN, Venlo, Netherlands). RNA was stored at -80 degrees until use. RNA (2 μL) was applied in an RNA-to-cDNA kit (Thermo Fisher Scientific). The reaction mixture was incubated at 37˚C for 60 minutes, and stopped by heating to 95˚C for 5 minutes and then held at 4˚C. After completion, the cDNA was stored at -20˚C. TaqMan Advanced Master Mix (18μl) and the Primer Probe Mixture (1μl) were added to 1 μL of RNA for a total volume of 20 μL. Primers and probes used for real-time PCR were created using the PAR2 TaqMan Gene Expression Assay (Thermo Fisher Scientific, MA, USA). The primers and probes for PAR2 (F2RL1) (accession number: Hs00608346_m1) and GAPDH (accession number: Hs99999905_m1) were purchased from Thermo Fisher Scientific.

**Evaluation of duodenal inflammatory cells and tight junction proteins**

Histological duodenitis was estimated as mild, moderate, or severe by H&E staining according to the criteria of previous studies [21,22]. Mild duodenitis was defined as an expansion of the lamina propria by mild inflammatory cell infiltration. Moderate duodenitis was determined by the partial loss of villi and expansion of the lamina propria by moderate inflammatory cell infiltration. Severe duodenitis was estimated by the partial loss of villi and expansion of the lamina propria by severe inflammatory cell infiltration, mainly consisting of plasma cells, macrophages, and lymphocytes. Specimens were estimated by two expert pathologists in a blinded manner. Migrated eosinophils were evaluated using HE staining.

CD68-positive cells, CCR2-positive cells, GLP-1 positive cells or degranulated eosinophils were analyzed by immunostaining using a mouse anti-CD68 antibody (DAKO, Glostrup, Denmark: 1:100), goat anti-CCR2 antibody (Abcam, CA, UK:1:200), rabbit anti-GLP-1 antibody (Abcam, Cambridge, UK; 1:2000) and mouse anti-PRG2 antibody (Gene Tex, CA, USA: 1:50), respectively.

In addition, tight junction proteins including claudin-1, occludin and ZO-1 were estimated by a mouse anti-claudin-1 antibody (Thermo Fisher Scientific, MA, USA: 1:200), rabbit anti-occludin antibody (Abcam, CA, UK: 1:500), rabbit anti-ZO-1 antibody (Abcam, CA, UK: 1:30), and rabbit anti-PAR2 antibody (NOVUS, CO, USA: 1:100), respectively.

Double-labeling immunofluorescence methods and confocal laser scanning microscopy were used to evaluate the coexpression of immunoreactivity for the pair of rabbit anti-EpCAM antibody (Abcam, CA, UK: 1:20) and mouse anti-PAR2 antibody (Santa Cruz, TX, USA: 1:20). In addition, we also determined the expression of immunoreactivity for the pair of mouse anti-PRG2 antibody (Gene, Tex, USA: 1:10) and rabbit anti-PAR2 antibody (NOVUS, CO, USA:1:10). Sections were incubated overnight at 4˚C with a mixture of the two primary antibodies and then with FITC or Texas red-conjugated secondary antibodies [horse anti-mouse IgG (Vector Laboratories, CA, USA) and goat anti-rabbit IgG (Vector Laboratories), for EpCAM and PAR2 or PRG2 and PAR2, respectively] followed by nuclear counterstaining with VECTSHIELD HardSet mounting medium with DAPI (Vector Laboratories).

**Scoring of immunostaining for tight junction proteins in the duodenum**

The expression levels of tight junction proteins were assessed by multiplying the scores according to a modified version of a previous study [23]. Briefly, each score between 1 and 3 was given to classify the percentage of positive cells (1, <25%; 2, 25–50%; 3, >50%) and the
intensity of membrane staining (1: mild staining, 2: moderate staining, 3: intense staining), respectively. The expression level of tight junction proteins (from 1 to 9) was defined by multiplying above two scores for positivity and intensity.

**Measurement of gastric emptying**

Sodium acetate (water soluble; $^{13}$C-acetate) was used as a tracer for the emptying of liquids (Cambridge Isotope Laboratories; Tewksbury, MA, USA). We used an integrated software solution program to calculate the half-gastric emptying time ($T_{1/2}$) and the lag phase ($T_{max}$; min) based on a previous study [24]. A $T_{max}$ value greater than 60 min, (representing the mean $T_{max}$ in healthy volunteers plus SD), was defined to identify relative disturbances in gastric emptying according to the diagnostic criteria of the Japan Society of Smooth Muscle Research and our study [13,25].

We determined the area under the curve at 5 minutes ($AUC_{5}$) and 15 minutes ($AUC_{15}$) values as markers of the early phase of gastric emptying based on previous studies [26,27].

**Sample size**

The sample size was determined using the Power and Sample Size Calculation Program (PS), gifted to us from Vanderbilt University. The standard deviation of the expression levels of occludin in ECP patients was approximately 1.8 ($σ$ = 1.8). Using the above data, and setting $α$ = 0.05, $β$ = 0.80, and the estimated mean of the expression levels of occludin in patients with ECP = 4.67, it was determined that 26ECP patients and 33FD-P patients were estimated to be sufficient to identify clinically relevant differences.

**Statistical analysis**

Statistical analysis was almost performed using two-tailed unpaired t-tests. The percentage of pancreatic enzyme abnormalities and endosonographic findings were performed using chi-square ($χ^2$) test. We examined tight junction proteins and inflammatory cells, and duodenal trypsin levels and serum trypsin levels using correlation coefficients. All analyses were performed using the standard software package (SPSS version 27.0, IBM Corp., Armonk, NY, USA) and p-values $<0.05$ were considered significant.

**Results**

**Clinical characteristics of ECP and FD-P patients**

Age, sex, BMI, $H. pylori$ positivity, and total GRSR score did not differ significantly between FD-P and ECP patients (Table 1). In addition, there were no significant differences in HbA$_{1C}$ values or proportion of peripheral eosinophils. On the other hand, immunoreactive insulin (IRI) values were significantly (p = 0.045) higher in patients with FD-P than in those with ECP (Table 1). In addition, positivity of abnormal PLA2 levels in FD-P patients was significantly (p = 0.028) higher compared to ECP patients. There were no significant differences in p-amylase, lipase, trypsin, and elastase-1 levels between ECP and FD-P groups (Table 1). Positivity of abnormal trypsin level was highest among all pancreatic enzymes (Table 1).

**Comparison of clinical symptoms between ECP and FD-P patients**

To determine whether there were any differences in clinical symptoms between ECP and FD-P patients, we compared bothersome FD symptoms, feeling of hunger, and discomfort for fat intake between ECP and FD patients. There were no differences in epigastric pain,
Comparison of Gastric Motility Between ECP Patients and FD-P Patients

To clarify whether there were significant differences in gastric emptying between ECP and FD-P patients, we measured $T_{\text{max}}$ and $T_{1/2}$ values such as gastric emptying, and $AUC_{5}$ and $AUC_{15}$ values such as the early phase of gastric emptying between ECP and FD-P patients. There were no significant differences in $T_{\text{max}}$ and $T_{1/2}$ values between ECP and FD-P patients (Fig 1B). In addition, there were no significant differences in $AUC_{5}$ and $AUC_{15}$ values between ECP and FD-P patients (Fig 1B).

In addition, there were no significant differences in $AUC_{5}$ and $AUC_{15}$ values between ECP and FD-P patients. We compared these using a two-tailed, unpaired, t-tests.

Comparison of endosonographic features between ECP and FD-P patients

We compared seven items of endosonographic features between patients with FD-P and those with ECP. Hyperechoic main pancreatic duct margin (14/26), lobularity with honeycombing (1/26), stranding (23/26), dilated side branches (3/26) and hyperechoic foci without shadowing (13/26) in ECP patients were significantly ($p<0.001$, $p<0.001$, $p<0.001$, $p=0.011$ and $p<0.001$, respectively) higher than those in FD-P patients (Fig 2A). Representative endosonographic features of patients with ECP are shown in Figure (Fig 2B).

Comparison of tight junction proteins expression in the duodenal mucosa between FD-P and ECP patients

Increased mucosal permeability is associated with changes in tight junction proteins in patients with FD. Thus, we compared the expression levels of occludin, claudin-1, and ZO-1 proteins in the duodenal mucosa of the patients with FD-P and ECP patients. The expression level of occludin in the duodenum of FD-P patients ($1.55\pm0.098$) was significantly reduced compared to that in ECP patients ($1.85\pm0.11$, $p = 0.043$) (Fig 3A). However, there were no
Fig 1. Comparison of bothersome FD symptoms and clinical symptoms between ECP and FD-P patients. 1A. There were not significant differences in epigastric pain, epigastric burning, postprandial fullness, early satiety, abdominal fullness, the feeling of hunger and discomfort for fat intakes between ECP and FD-P patients. 1B. Comparison of gastric motility between ECP and FD-P patients. There were no significant differences in Tmax and T1/2 values between early chronic pancreatitis (ECP) and FD patients with pancreatic enzyme abnormalities (FD-P).

https://doi.org/10.1371/journal.pone.0275341.g001
### A

| Endosonographic features                          | FD-P (n=54) | ECP (n=26) | P value |
|--------------------------------------------------|-------------|------------|---------|
| Lobularity with honeycombing                    | 1/54        | 1/26       | <0.001  |
| Lobularity without honeycombing                 | 0/54        | 2/26       | 0.039   |
| Hyperechoic foci without shadowing              | 3/54        | 13/26      | <0.001  |
| Strandng                                        | 12/54       | 23/26      | <0.001  |
| Cysts                                           | 1/54        | 0/26       | 0.485   |
| Dilated side branches                           | 0/54        | 3/26       | 0.011   |
| Hyperechoic main pancreatic ductal margin      | 6/54        | 14/26      | <0.001  |

ECP: early chronic pancreatitis  
FD-P: functional dyspepsia with pancreatic enzyme abnormalities

### B

**Fig 2. Comparison of endosonographic features between ECP and FD-P patients.**  
Fig 2A We compared seven items of endosonographic features between FD-P and ECP patients. Fig 2B. We showed representative endosonographic features (lobularity with honeycombing, lobularity without honeycombing, hyperechoic foci without shadowing, stranding, cyst, dilated side branches, and hyperechoic main pancreatic ductal margin) of patients with ECP. Arrows show lobularity with honeycombing or dilated side branches, or hyperechoic main pancreatic ductal margin.

[https://doi.org/10.1371/journal.pone.0275341.g002](https://doi.org/10.1371/journal.pone.0275341.g002)
significant differences in ZO-1 (ECP:2.05 ± 0.08, FD-P:2.00 ± 0.01) and claudin-1 (ECP:1.08 ± 0.06, FD-P:1.00 ± 0.01) expressions in the duodenal mucosa between ECP and FD-P patients (Fig 3A).

**Comparison of eosinophils, CD68-, GLP-1-, PRG2-, and CCR2-positive cells between ECP and FD-P patients**

Since duodenal inflammation was observed in patients with FD-P and ECP in our previous study, we compared the expression levels of inflammatory cells, including eosinophils, CD68-
positive cells, CCR2-positive cells, GLP-1 producing cells, and PRG-2 positive cells between the two groups. The CD68-positive cells counts (87.84±5.63) in the duodenum of ECP patients were significantly (p<0.01) higher than that of FD-P patients (26.78±3.96) (Fig 3B). In addition, eosinophils counts (11.19±0.81) in the duodenum of FD-P patients were significantly (p = 0.008) higher than those of ECP patients (8.81±0.75). However, there were no significant differences in the infiltrations of GL-P-1 positive cells (FD-P: 9.02±0.97, ECP: 11.39±3.4), degranulated eosinophils (FD-P: 3.55±0.74, ECP: 3.19±1.48) and CCR-2-positive cells (FD-P: 0.9 ±0.40, ECP: 0.21±0.09) in the duodenum between patients with ECP and FD-P (Fig 3B).

**Correlation between CD68-positive cells or degranulated eosinophils infiltration and the expression levels of occludin in ECP and FD-P patients**

To determine whether duodenal inflammatory cells, such as CD68-positive cells or eosinophils, are associated with the expression levels of tight junction proteins, such as occludin, we compared their association in the duodenum of patients with ECP and FD-P. There was no significant correlation between CD68-positive cells infiltration and occludin expression levels in ECP (R² = 0.1, p = 0.66) and FD-P (R² = 0.1, p = 0.61) patients (Fig 4A and 4B). In addition, there was not significant correlation between degranulated eosinophils and occludin expression levels in ECP (R² = 0.31, p = 0.16) and FD-P patients (R² = -0.22, p = 0.27) (Fig 4C and 4D).

![Relationship between CD68-positive cells or degranulated eosinophils and occludin between ECP and FD-P patients](https://doi.org/10.1371/journal.pone.0275341.g004)
Trypsin levels were associated with peripheral and duodenal eosinophils in ECP and FD-P patients

To determine whether serum trypsin levels were associated with peripheral and duodenal eosinophils and duodenal inflammatory responses such as duodenal eosinophils count in ECP and FD-P patients, we compared serum trypsin levels with peripheral and duodenal eosinophils counts between ECP and FD-P patients. Interestingly, serum trypsin levels were significantly ($p = 0.007$) associated with peripheral eosinophils counts in patients with ECP (Fig 5A). In addition, serum trypsin levels were also significantly ($p<0.05$ and $p<0.001$, respectively) correlated with the duodenal eosinophils counts in ECP and FD-P patients (Fig 5A and 5B). Furthermore, 78.3% (20/26) of patients with ECP and 81.5% (44/54) of patients with FD-P exhibited elevated serum trypsin levels.

Relationship between serum trypsin level and duodenal trypsin level in ECP and FD-P patients

Since positivity of abnormal trypsin level was highest among all pancreatic enzymes in ECP and FD-P patients, we focused on the relationship between serum and duodenal trypsin levels in ECP and FD-P patients. There was a mild relationship ($R^2 = 0.022$, $p = 0.36$) between serum trypsin levels and duodenal trypsin levels in patients with ECP and FD-P (Fig 6).

Comparison of PAR2 mRNA levels in the duodenal mucosa of FD-P ECP patients

To determine the expression levels of the trypsin receptor, PAR2 in the duodenal mucosa of patients with ECP and FD-P, we compared PAR2 mRNA levels in duodenal tissues among ECP patients, FD-P patients and asymptomatic patients. PAR2 mRNA levels in duodenal mucosa of patients with ECP and FD-P were significantly ($p<0.01$) increased compared to those in asymptomatic patients using real-time PCR (Fig 7). However, there were no significant differences in PAR2 mRNA levels in the duodenal mucosa between ECP and FD-P patients (Fig 7).

Localization of PAR2 and degranulated eosinophils expression in the duodenum of patients with ECP and FD-P

To clarify the localization of PAR2 expression in the duodenal mucosa of patients with ECP and FD-P, we compared the localization of PAR2-positive cells in the duodenum between the two groups using immunostaining. PAR2 was expressed in the epithelial cells and the surface of mononuclear cells in the duodenal mucosa of ECP and FD-P patients (Fig 8A and 8B). In addition, degranulated eosinophils were localized beneath the epithelial cells (Fig 8C and 8D) in the duodenal mucosa of ECP and FD-P patients using anti-PRG2 antibody.

In Fig 9A, FITC-labeled (green) cells in the duodenum of patients with FD-P in show PAR2 immunoreactivity. Texas-red-conjugated cells in Fig 9A show EpCAM immunoreactivity for the same section (Fig 9A). There were many double-positive-stained cells (yellow cells) for the same section (Fig 9A). In addition, FITC-labeled (green) cells in the duodenum of patients with FD-P in Fig 9B show PRG2 immunoreactivity (Fig 9B). Texas-red-conjugated cells in Fig 9B show PAR2 immunoreactivity for the same section (Fig 9B). There were several double-positive-stained cells (yellow cells) for the same section (Fig 9B).
Fig 5. Trypsin levels were associated with peripheral and duodenal eosinophils counts in ECP and FD-P patients. Serum trypsin levels were significantly (p = 0.007, $R^2 = 0.549$) associated with peripheral eosinophils counts in patients with ECP (Fig 5A). In addition, serum trypsin level was not significantly (p = 0.05, $R^2 = 0.267$) associated with peripheral eosinophils counts in FD-P patients (Fig 5B). In addition, serum trypsin levels in ECP and FD-P patients were also significantly (p<0.05, $R^2 = 0.419$ and p<0.001, $R^2 = 0.838$, respectively) correlated with duodenal eosinophils counts (Fig 5A and 5B). These groups were compared using a correlation coefficient.

https://doi.org/10.1371/journal.pone.0275341.g005
Association between elevated trypsin levels and occludin or ZO-1 expression levels, and degranulated eosinophils infiltrations in the duodenum of patients with ECP and FD-P

To determine whether elevated trypsin levels (n = 64, 64/80) affected with the expression levels of tight junction proteins and the migration of degranulated eosinophils in patients with ECP and FD-P, we investigated whether elevated trypsin levels were associated with the expression levels of occludin and ZO-1 or with degranulated eosinophils in the duodenum of patients with ECP and FD-P. Elevated trypsin (64/80) were not significantly associated with occludin ($R^2 = 0.27$, $p = 0.24$ and $R^2 = 0.06$, $p = 0.77$), ZO-1 ($R^2 = 0.23$, $p = 0.33$ and $R^2 = 0.31$, $p = 0.25$) or degranulated eosinophils expression levels in the duodenum ($R^2 = -0.21$, $p = 0.42$ and $R^2 = -0.14$, $p = 0.55$) in patients with ECP and FD-P (S2A–S2F Fig).

Discussion

Main findings in this study are 1) although there were no significant differences in clinical symptoms and gastric motility between ECP and FD-P patients, the scores of certain endosonographic features such as lobularity with honeycombing, hyperechoic foci without shadowing, stranding, dilated side branches, and hyperechoic main pancreatic ductal margin were significantly higher in ECP patients compared to those of FD-P patients, 2) CD68-positive cells infiltrations and the expression levels of occludin in the duodenum were significantly
reduced in FD-P patients compared to those of ECP patients, 3) serum trypsin levels in ECP patients were significantly \((p = 0.007)\) associated with peripheral eosinophils and serum trypsin levels in ECP and FD-P patients were significantly \((p < 0.05 \text{ and } p < 0.001, \text{ respectively})\) associated with duodenal eosinophils respectively, 4) PAR2 expression localized in epithelial cells of the duodenum and degranulated eosinophils in patients with ECP and FD-P.

Since CP has a high mortality rate owing to a variety of factors, it is critical to identify CP at its early stage [28,29]. Some studies have reported that dyspeptic symptoms and symptoms consisting with irritable bowel syndrome may be the first and single clinical manifestation of chronic pancreatitis [30,31]. Therefore, it is very important to differentiate clinical characteristics and FD symptoms between these two cohorts of patients. Masamune et al have reported that the great majority of ECP cases did not develop into definite CP after two-year follow-up [32]. In addition, in the present study two cases (2/33) of patients with FD-P advanced into ECP patients, these may have actually been cases of ECP patients at an early stage. In our study, lobularity with honeycombing, hyperechoic foci without shadowing, stranding, dilated side branches, and hyperechoic main pancreatic ductal margin in endosonographic features were significantly higher in ECP patients compared to FD-P patients. We have also reported that non-alcoholic related ECP patients did not develop chronic pancreatitis. Diagnosis of FD-P patients based on no abnormal findings on upper GI endoscopy, abdominal US, and CT scan could not be completely excluded ECP patients without endosonography. In addition, in

![Fig 7. Comparison of PAR2 mRNA levels in duodenal mucosa of FD-P patients with ECP patients. PAR2 mRNA relative expression in the duodenal mucosa of patients with ECP (n = 4) and FD-P (n = 4) were significantly higher than those of asymptomatic patients (n = 12) using real-time PCR (Fig 7). However, there were no significant differences in PAR2 mRNA relative expression in the duodenal mucosa between ECP and FD-P patients (Fig 7). Results were compared using two-tailed, unpaired, t-tests.](https://doi.org/10.1371/journal.pone.0275341.g007)
our data, exocrine pancreatic dysfunction in patients with FD-P was widely observed as well as previous study [33,34]. Exocrine pancreatic function is regulated by gut hormones such as CCK and 5-HT [35,36] and is associated with gastric emptying [37,38]. Therefore, FD-P concomitant with the impairment of gastric emptying induced by exocrine pancreatic dysfunction and abnormal activities of gut hormones, may be a prestage of early chronic pancreatitis. Further studies will be needed to clarify which types of FD-P patients will advance to ECP patients.

Considering that the hyperechoic main pancreatic ductal margin, lobularity and dilated side branches vanished after treatment in our previous study [11], we hypothesize that certain endosonographic features described in Fig 1 may be reversible in ECP and FD-P patients. The tight junction proteins are essential components of the intestinal barrier and consist of transmembrane proteins, such as occludin and claudin-1 [39]. Increased mucosal permeability, changes in tight junction proteins, and other pathological findings caused by slight inflammation have been studied in several gastrointestinal diseases [40–42]. Knockdown of occludin results in increased permeability, and the downregulation of occludin has been implicated in intestinal diseases [43]. Chang et al. have also reported that the expression of occludin and claudin-1 may be significantly reduced in FD rats by stress [44]. Lee et al. also reported that occludin expression levels were significantly lower in stressed rats than in controls [45]. Thus, the pathophysiology of patients with FD is reportedly associated with psychological stress.

Fig 8. Location of PAR2 expression in the duodenum of patients of FD-P and ECP. PAR2 expression was localized in the duodenal epithelial cells and eosinophils in ECP and FD-P patients (Fig 8A and 8B). In addition, degranulated eosinophils were localized beneath the epithelial cells (Fig 8C and 8D) in the duodenal mucosa of patients with ECP and FD-P. Arrows (▼) showed PAR2-positive epithelial cells in the duodenum of patients with ECP and FD-P (Fig 8A and 8B). Arrows (▲) demonstrated PRG2-positive degranulated eosinophils in the duodenum of patients with ECP and FD-P using anti-PRG2 antibody (Fig 8C and 8D).
Considering of previous reports and our data, a significant reduction of occludin levels in the duodenum of patients with FD-P may also be associated with the stress. Cheng et al. have reported that claudin-1 expression levels were reduced in patients with diarrhea-predominant IBS [46]. Although ZO-1 and claudin expression levels in the duodenum have been reported to be associated with FD patients, respectively [47,48], in our data, there were no significant differences in ZO-1 and claudin-1 expression levels between FD-P and ECP patients.

Duodenal inflammation has also been linked to FD [12,49,50]. Vanheel et al discovered that not only eosinophils, but also mast cells, were found to be increased in the duodenum of patients with FD [49]. In our data, a significant elevation of eosinophils counts in patients with FD-P as described in Fig 3B may be partly reflected in the enhancement of duodenal permeability. However, there was no significant difference in the number of degranulated eosinophils between FD-P and ECP patients. These discrepancies between eosinophils and degranulated eosinophils counts in the duodenum may be dependent on the possibilities that degranulated eosinophils have been reported to be associated with the combination of eotaxin-3 and IL-5 [51]. Further studies will be needed to clarify the reason why duodenal inflammation occurred and was sustained in patients with FD. In addition, although we tried to clarify whether CD68-positive cells or granulated eosinophils were associated with the

---

**Fig 9. Colocalization of PAR2 and EpCAM or PAR2 and degranulated eosinophils in the duodenum of patients with FD-P.** Fig 9A. PAR2-positive cells (green cells) in the duodenum of patients with FD-P. EpCAM-positive cells (red cells) in the duodenum of patients with FD-P. PAR2 and EpCAM expressions were mainly coexpressed in the same section. Double-positive cells (yellow cells) reveal PAR2- and EpCAM-positive cells in the same section. 4', 6-diamidino-2-phenylindole staining (blue cells). Fig 9B. PRG2-positive cells (green cells) in the duodenum of patients with FD-P. PAR2-positive cells (red cells) in the duodenum of patients with FD-P. PRG2 and PAR2 expressions were coexpressed in the same section. Double-positive cells (yellow cells) reveal PRG2- and PAR2-positive cells in the same section. 4', 6-diamidino-2-phenylindole staining (blue cells).

https://doi.org/10.1371/journal.pone.0275341.g009
reduction of tight junction proteins such as claudin-1, ZO-1, and occludin in the duodenum, CD68-positive cells and granulated eosinophils were not associated with tight junctions in the duodenum of patients with FD-P.

Reed et al. also reported that PAR2 stimulation of epithelial cells opens tight junctions, causes desquamation, and produces cytokines and growth factors [52]. Miike et al. reported that human eosinophils expressed mRNA for PAR2 and trypsin, an agonist for PAR2, induced degradation of eosinophils [53]. Edogawa et al. also reported that the activation of PAR2 diminished the expression levels of tight junction proteins in patients with irritable bowel syndrome [54]. Considering previous studies and the significant relationship between trypsin levels and duodenal eosinophils, trypsin may be associated with eosinophils through the activation of PAR2 in the duodenal mucosa or on the surface of the eosinophils itself (graphical summary). In addition, trypsin levels may be associated with the reduction of occludin expression levels in the duodenum of patients with ECP through the activation of PAR2, albeit not statistically significant. Nestor et al. also reported that PAR2 expression has been reported in the colon of patients with IBS [55]. We are first to report that PAR2 mRNA and protein levels were determined in the duodenal mucosa of patients with FD-P and ECP (graphical summary). The association between duodenal degranulated eosinophils counts and trypsin levels did not reflect on a significant relationship between trypsin levels and peripheral eosinophils counts. Considering the above issues, eosinophil degranulation in the duodenum may require not only PAR2 stimulation with trypsin but also the existence of other inflammatory factors in the duodenum. The migration of duodenal degranulated eosinophils may require the coordinated activation of PAR2 and other inflammatory pathways, such as activated mast cells [56] or IL-33 production [57].

Taken together, our data suggest that elevated trypsin levels might be partly associated with duodenal inflammatory responses through PAR2-related duodenal epithelium and eosinophils infiltrations and the reduction of occludin in patients with ECP and FD-P.

**Supporting information**

S1 Checklist.

(DOCTYPE)

S1 Fig. Study protocol.

(TIF)

S2 Fig. Relationship between elevated trypsin levels and occludin, ZO-1 and degranulated eosinophils expression levels between ECP and FD-P patients. There was no significant relationship between elevated trypsin levels and occlusion or ZO-1 expression levels in ECP and FD-P patients (S2A, S2B, S2C, and S2D Fig). In addition, elevated trypsin levels were not associated with degranulated eosinophils infiltration in ECP and FD-P patients (S2E and S2F Fig). These groups were compared using a correlation coefficient.

(TIF)

**Author Contributions**

Data curation: Shuhei Agawa, Seiji Futagami, Hiroshi Yamawaki, Rina Tsushima, Kazutoshi Higuchi, Mayu Habiro, Rie Kawawa, Yasuhiro Kodaka, Nobue Ueki, Yoshiyuki Watanabe, Katya Gudis, Rhuji Ohashi, Katsuhiko Iwakiri.

Formal analysis: Shuhei Agawa.

Funding acquisition: Seiji Futagami.
Investigation: Shuhei Agawa, Seiji Futagami.
Writing – original draft: Seiji Futagami.
Writing – review & editing: Seiji Futagami.

References
1. Drossman DA. The functional gastrointestinal disorders and the Rome III process. Gastroenterology. 2006; 130: 1377–1390. https://doi.org/10.1053/j.gastro.2006.03.008 PMID: 16678553
2. Tack J, Talley NJ, Camilleri M, Holtmann G, Hu P, Malagelada JR, et al. Functional gastroduodenal disorders. Gastroenterology. 2006; 130: 1466–1479. https://doi.org/10.1053/j.gastro.2005.11.059 PMID: 16678560
3. Sahai AV, Mishra G, Penman ID, Williams D, Wallace MB, Hadzijahic N, et al. EUS to detect evidence of pancreatic disease in patients with persistent or non-specific dyspepsia. Gastrointest Endosc. 2000; 52: 153–159. https://doi.org/10.1016/S0016-5107(00)71739-7 PMID: 10922084
4. Andersen BN, Scheel J, Rune SJ, Worning H. Exocrine pancreatic function in patients with dyspepsia. Hepatogastroenterology. 1982; 29: 35–37. PMID: 7095736
5. Smith RC, Talley NJ, Dent OF, Jones M, Waller SL. Exocrine pancreatic function and chronic unexplained dyspepsia: a case-control study. Int J Pancreatol. 1991; 8: 253–262. https://doi.org/10.1007/BF02924544 PMID: 2051063
6. Miwa H, Kusano M, Arisawa T, Oshima T, Kato M, Joh T, et al. Evidence-based clinical practice guidelines for functional dyspepsia. J Gastroenterol. 2015; 50: 125–139. https://doi.org/10.1007/s00535-014-1022-3 PMID: 25586651
7. Ito T, Ishiguro H, Ohara H, Kamisawa T, Sakagami J, Sata N, et al. Evidence-based clinical practice guidelines for chronic pancreatitis 2015. J Gastroenterol. 2016; 51: 85–92. https://doi.org/10.1007/s00535-015-1149-x PMID: 26725837
8. Hashimoto S, Futagami S, Yamawaki H, et al. Epigastric pain syndrome accompanying pancreatic enzyme abnormalities was overlapped with early chronic pancreatitis using endosonography. J Clin Biochem Nutr. 2017; 61: 140–145. https://doi.org/10.3164/jcbn.17-41 PMID: 28955132
9. Wakabayashi M, Futagami S, Yamawaki H, Tatsuguchi A, Kaneko K, Agawa S, et al. Comparison of clinical symptoms, gastric motility and fat intake in the early chronic pancreatitis patients with anti-acid therapy-resistant functional dyspepsia patients. PLoS One. 2018; 13: e0205165. https://doi.org/10.1371/journal.pone.0205165 PMID: 30403664
10. Yamawaki H, Futagami S, Kaneko K, Agawa S, Higuchi K, Murakami M, et al. Camostat mesilate, pancrelipase and rabeprazole combination therapy improves epigastric pain in early chronic pancreatitis and functional dyspepsia with pancreatic enzyme abnormalities. Digestion 2019; 99: 283–292. https://doi.org/10.1159/000492813 PMID: 30391941
11. Higuchi K, Futagami S, Yamawaki H, Murakami M, Kirita K, Agawa S, et al. Endosonographic features in patients with non-alcoholic early chronic pancreatitis improved with treatment at one year follow up. J Clin Biochem Nutr 2021; 68: 86–94. https://doi.org/10.3164/jcbn.19-130 PMID: 33536717
12. Du L, Shen J, Kim JJ, Yu Y, Ma L, Dai N. Increased Duodenal Eosinophil Degranulation in Patients with Functional Dyspepsia: A Prospective Study. Sci Rep. 2016; 6: 34305. https://doi.org/10.1038/srep34305 PMID: 27708358
13. Futagami S, Shindo T, Kawagoe T, Horie A, Shimpuku M, Gudis K, et al. Migration of eosinophils and CCR2-/CD68-positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010; 105: 1835–1842. https://doi.org/10.1038/aig.2010.151 PMID: 20461070
14. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita AY, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014; 63: 262–271. https://doi.org/10.1136/gutjnl-2012-303857 PMID: 23474421
15. Larrache M. Novel insights in the role of peripheral corticotropin-releasing factor and mast cells in stress-induced visceral hypersensitivity. Neurogastroenterol Motil. 2012; 24: 201–205. https://doi.org/10.1111/j.1365-2928.2011.01867.x PMID: 22316289
16. Kong W, McConalogue K, Khitin LM, Hollenberg MD, Payan DG, Böhm SK, et al. Luminal trypsin may regulate enterocytes through proteinase-activated receptor 2. Proc Natl Acad Sci U S A. 1997; 94: 8884–8889. https://doi.org/10.1073/pnas.94.16.8884 PMID: 9238072
17. Hjortoe GM, Petersen LC, Albrektsen T, Sorensen BB, Norby PL, Mandal SK, et al. Tissue factor-factor VIIa-specific up-regulation of IL-8 expression in MDA-MB-231 cells is mediated by PAR-2 and results in increased cell migration. Blood. 2004; 103: 3029–3037. https://doi.org/10.1182/blood-2003-10-3417 PMID: 15070680

18. Johansson U, Lawson C, Dabare M, Syndercombe-Court D, Newland AC, Howells GL, et al. Human peripheral blood monocytes express protease receptor-2 and respond to receptor activation by production of IL-6, IL-8, and IL-1(β). J Leukoc Biol. 2005; 78: 967–975. https://doi.org/10.1189/jlb.0704422 PMID: 16000389

19. Svedlund J, Sjodin I, Dotevall G. GSRS—a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci. 1988; 33: 129–134. https://doi.org/10.1007/BF01535722 PMID: 3123181

20. Engbers LH, van Poppel MN, A Paw MC, van Mechelen W. The effects of a controlled worksite environmental intervention on determinants of dietary behavior and self-reported fruit, vegetable and fat intake. BMC Public Health. 2006; 6: 253. https://doi.org/10.1186/1471-2458-6-253 PMID: 17044395

21. Elta GH, Appelman HD, Behler EM, Wilson JA, Nostrand TJ. A study of the correlation between endoscopic and histological diagnoses in gastroduodenitis. Am J Gastroenterol. 1987; 82: 749–753. PMID: 3300278

22. Elta GH, Murphy R, Behler EM, Barnett JL, Nostrand TT, Kern S, et al. Campylobacter pylori in patients with dyspeptic symptoms and endoscopic evidence of erosion(s). Am J Gastroenterol. 1989; 84: 643–646.

23. Skalova H, Hájková N, Majerová B, Bártu M, Povysil C, Tichá L. Impact of chemotherapy on the expression of claudins and cadherins in invasive breast cancer. Experimental and Therapeutic Medicine. 2019; 18: 3014–3024. https://doi.org/10.3892/etm.2019.9790 PMID: 31572543

24. Hellmig S, Schöning FV, Gadow C, Katsoulis S, Hedderich J, Fölsch UR, et al. Gastric emptying time of fluids and solids in healthy subjects determined by 13C breath tests: influence of age, sex and body mass index. J Gastroenterol Hepatol. 2006; 21: 1832–1838. https://doi.org/10.1111/j.1440-1746.2006.04449.x PMID: 17074022

25. Shindo T, Futagami S, Hiratsuka T, Horie A, Hamamoto T, Ueki N, et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009; 79: 65–72. https://doi.org/10.1159/000205740 PMID: 19246923

26. Shimpuku M, Futagami S, Inamori M, Yamawaki H, Sato H, Kodaka Y, et al. Distinct associations between depression status and initial phase of gastric emptying in functional dyspepsia and healthy volunteers. Int J Gastroenterol Disord Ther. 2014; 1: 106–11. http://dx.doi.org/10.15344/2393-8498/2014/106.

27. Yamawaki H, Futagami S, Shimpuku M, Shindo T, Maruki Y, Nagoya H, et al. Leu72Met 408 Polymorphism of the Ghrelin Gene Is Associated With Early Phase of Gastric Emptying in the Patients With Functional Dyspepsia in Japan. J Neurogastroenterol Motil. 2015; 21: 93–102. https://doi.org/10.5056/jnm14086 PMID: 25540946

28. de la Iglesia-García D, Vallejo-Senra N, Iglesias-García J, López-López A, Nieto L, Domínguez-Muñoz JE. Increased Risk of Mortality Associated With Pancreatic Exocrine Insufficiency in Patients With Chronic Pancreatitis. J Clin Gastroenterol. 2018; 52: e63–e72. https://doi.org/10.1097/MCG.0000000000000917 PMID: 28858943

29. Lankisch PG. Natural course of chronic pancreatitis. Pancreatology. 2001; 1: 3–14. https://doi.org/10.1159/000005578 PMID: 12120264

30. Lee YT, Lai ACW, Hui Y, Wu JC, Leung VK, Chan FK, et al. EUS in the management of uninvestigated dyspepsia. Gastrointest Endosc. 2002; 56: 842–848. https://doi.org/10.1016/s0016-5107(02)00359-4 PMID: 12447295

31. Leeds JS, Hopper AD, Sidhu R, Simmonette A, Azadakht H, Hoggard N, et al. Some patients with irritable bowel syndrome may have exocrine pancreatic insufficiency. Clin Gastroenterol Hepatol. 2010; 8: 433–438. https://doi.org/10.1016/j.cgh.2009.09.032 PMID: 19835990

32. Masamune A, Nabeshima T, Kikuta K, Hamada S, Nakano E, Kume K, et al. Prospective study of early chronic pancreatitis diagnosed based on the Japanese diagnostic criteria. J Gastroenterol. 2019; 54: 928–935. https://doi.org/10.1007/s00535-019-01602-9 PMID: 31270692

33. Agawa S, Futagami S, Yamawaki H, Gudis K, Higuchi K, Kaneko K, et al. State of anxiety may be associated with exocrine pancreatic insufficiency in functional dyspepsia patients with pancreatic enzyme abnormalities. JCBN. Forthcoming 2021. https://doi.org/10.3164/jcbn.21-67 PMID: 35400815

34. Fujiwara Y, Tominaga K, Tanaka F, Kamata N, Yamagami H, Tanigawa T, et al. Postprandial Symptoms Felt at the Lower Part of the Epigastrum and a Possible Association of Pancreatic Exocrine Dysfunction with the Pathogenesis of Functional Dyspepsia. Intern Med. 2017; 56: 1629–1635. https://doi.org/10.2169/internalmedicine.56.8193 PMID: 28674349
35. Li Y, Owyang C. Endogenous cholecystokinin stimulates pancreatic enzyme secretion via vagal afferent pathway in rats. Gastroenterology. 1994; 107: 525–31. https://doi.org/10.1016/0016-5085(94)90180-5 PMID: 8039628

36. Li Y, Wu XY, Zhu JX, Owyang C. Intestinal serotonin acts as paracrine substance to mediate pancreatic secretion stimulated by luminal factors. Am J Physiol Gastrointest Liver Physiol. 2001; 281: G916–G923. https://doi.org/10.1152/ajpgi.2001.281.4.G916 PMID: 11557511

37. Alkaade S, Vareeddayah AA. A primer on exocrine pancreatic insufficiency, fat malabsorption, and fatty acid abnormalities. Am J Manag Care. 2017; 23: S203–S209. PMID: 28727477

38. Mussa BM, Sood S, Verberne AJ. Implication of neurohormonal-coupled mechanisms of gastric emptying and pancreatic secretory function in diabetic gastroparesis. World J Gastroenterol. 2018; 24: 3821–3833. https://doi.org/10.3748/wjg.v24.i34.3821 PMID: 30228777

39. Van Itallie CM, Anderson JM. Architecture of tight junctions and principles of molecular composition. Am J Manag Care. 2017; 23: S203–S209. PMID: 28727477

40. Bjarnason I, Williams P, So A, Zanelli GD, Levi AJ, Gumpel JM, et al. Intestinal permeability and inflammation in rheumatoid arthritis: effects of non-steroidal anti-inflammatory drugs. Lancet. 1984; 2: 1171–1174. https://doi.org/10.1016/s0140-6736(84)92739-9 PMID: 6150232

41. Olaison G, Leandersson P, Sjödahl R, Tagesson C. Increase in Permeability and Phospholipase A2 Activity of Colonic Mucosa in Crohn’s Colitis. Digestion. 1989; 43: 228–233. https://doi.org/10.1159/000199881 PMID: 2612746

42. Oshima T, Miwa H, Joh T. Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol. 2008; 23 Suppl 2: S146–150. https://doi.org/10.1111/j.1440-1746.2008.05405.x PMID: 19120888

43. Feldman GJ, Mullin JM, Ryan MP. Occludin: structure, function and regulation. Adv Drug Deliv Rev. 2005; 57: 883–917. https://doi.org/10.1016/j.addr.2005.01.009 PMID: 15820558

44. Chang X, Zhao L, Wang J, Lu X, Zhang S. Sini-san improves duodenal tight junction integrity in a rat model of functional dyspepsia. J Gastroenterol Hepatol. 2008; 23 Suppl 2: S146–150. https://doi.org/10.1111/j.1440-1746.2008.05405.x PMID: 19120888

45. Lee HS, Kim DK, Kim YB, Lee KJ. Effect of acute stress on immune cell counts and the expression of tight junction proteins in the duodenal mucosa of rats. Gut Liver. 2013; 2: 190–196. https://doi.org/10.5009/gnl.2013.7.2.190 PMID: 23560155

46. Cheng P, Yao J, Wang C, Zhang L, Kong W. Molecular and cellular mechanisms of tight junction dysfunction in the irritable bowel syndrome. Mol Med Rep. 2015; 12: 3257–3264. https://doi.org/10.3892/mmr.2015.3808 PMID: 25998845

47. Komori K, Ihara E, Minoda Y, Ogino H, Sasaki T, Fujwara M, et al. The altered mucosal barrier function in the duodenum plays a role in the pathogenesis of functional dyspepsia. Dig Dis Sci. 2019; 64: 3228–3239. https://doi.org/10.1007/s10620-019-5470-8 PMID: 30673985

48. Taki M, Oshima T, Li M, Sei H, Tozawa K, Tomita T, et al. Duodenal low-grade inflammation and expression of tight junction proteins in functional dyspepsia. Neurogastroenterol Motil. 2019; 31: e13576. https://doi.org/10.1111/nmo.13576 PMID: 30793078

49. Vanheel H, Vicario M, Vanuytsel T, Van Oudenhove L, Martinez C, Keita ÅV, et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014; 63: 262–271. https://doi.org/10.1136/gutjnl-2013-303857 PMID: 23474421

50. Yuan HP, Li Z, Zhang Y, Li X, Li F, Li Y. Anxiety and depression are associated with increased counts and degranulation of duodenal mast cells in functional dyspepsia. Int J Clin Exp Med. 2015; 8: 8010–8014. PMID: 26221363

51. Badewa AP, Heiman AS. Inhibition of CCL11, CCL24, and CCL26-induced degranulation in HL-60 eosinophilic cells by specific inhibitors of MEK1/MEK2, p38 MAP kinase, and PI 3-kinase. Immuno pharmacology and Immunotoxicology. 2003; 25: 145–157. https://doi.org/10.1081/iph-120020466 PMID: 12784909

52. Reed CE, Kita H. The role of protease activation of inflammation in allergic respiratory diseases. J Allergy Clin Immunol. 2004; 114: 997–1008. https://doi.org/10.1016/j.jaci.2004.07.060 PMID: 15536399

53. Mike S, McWilliam AS, Kita H. Trypsin induces activation and inflammatory mediator release from human eosinophils through protease-activated receptor-2. J Immunol. 2001; 167: 6615–6622. https:// doi.org/10.4049/jimmunol.167.11.6615 PMID: 11714832

54. Edogawa S, Edwinson AL, Peters SA, Chikkamahalli LL, Sundt W, Graves S, et al. Serine proteases as luminal mediators of intestinal barrier dysfunction and symptom severity in IBS. Gut. 2020; 69: 62–73. https://doi.org/10.1136/gutjnl-2018-317416 PMID: 30923071
55. Jimenez-Vargas NN, Pattison LA, Zhao P, Lieu T, Latorre R, Jensen DD, et al. Protease-activated receptor-2 in endosomes signals persistent pain of irritable bowel syndrome. Proc Natl Acad Sci U S A. 2018; 115: E7438–E7447. https://doi.org/10.1073/pnas.1721891115 PMID: 30012612

56. Miwa H, Oshima T, Tomita T, Fukui H, Kondo T, Yamasaki T, et al. Recent understanding of the pathophysiology of functional dyspepsia: role of the duodenum as the pathogenic center. J Gastroenterol 2019; 54: 305–311. https://doi.org/10.1007/s00535-019-01550-4 PMID: 30767076

57. De Salvo C, Wang XM, Pastorelli L, Mattioli B, Omenetti S, Buela KA, et al. IL-33 drives eosinophil infiltration and pathogenic type 2 helper T-cell immune responses leading to chronic experimental ileitis. Am J Pathol, 2016; 186: 885–898. https://doi.org/10.1016/j.ajpath.2015.11.028 PMID: 26908008